Nektar Therapeutics (NASDAQ: NKTR) on Monday, soared 8.03% from the previous trading day, before settling in for the closing price of $54.28. Within the past 52 weeks, NKTR’s price has moved between $0.43 and $66.92.
Healthcare Sector giant saw their annual sales surged by 25.49% over the last five years. The company achieved an average annual earnings per share of -14.79%. With a float of $20.06 million, this company’s outstanding shares have now reached $20.34 million.
Nektar Therapeutics (NKTR) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Nektar Therapeutics is 1.40%, while institutional ownership is 70.51%. The most recent insider transaction that took place on Sep 09 ’25, was worth 311,214. In this transaction President & CEO of this company sold 6,666 shares at a rate of $46.69, taking the stock ownership to the 49,342 shares. Before that another transaction happened on Sep 09 ’25, when Company’s Officer proposed sale 6,666 for $46.69, making the entire transaction worth $311,205.
Nektar Therapeutics (NKTR) Earnings and Forecasts
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -2.25 earnings per share (EPS) for the period topping the consensus outlook (set at -2.92) by 0.67. Wall Street market experts anticipate that the next fiscal year will bring earnings of -2.59 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -14.79% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -7.79% during the next five years compared to 25.49% growth over the previous five years of trading.
Nektar Therapeutics (NASDAQ: NKTR) Trading Performance Indicators
Nektar Therapeutics (NKTR) is currently performing well based on its current performance indicators. A quick ratio of 4.24 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 19.05.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -7.94, a number that is poised to hit -2.51 in the next quarter and is forecasted to reach -9.55 in one year’s time.
Technical Analysis of Nektar Therapeutics (NKTR)
Analysing the last 5-days average volume posted by the [Nektar Therapeutics, NKTR], we can find that recorded value of 0.68 million was lower than the volume posted last year of 0.9 million. As of the previous 9 days, the stock’s Stochastic %D was 37.72%.
During the past 100 days, Nektar Therapeutics’s (NKTR) raw stochastic average was set at 81.96%, which indicates a significant increase from 65.99% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 3.72 in the past 14 days, which was higher than the 3.08 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $58.10, while its 200-day Moving Average is $27.70. Now, the first resistance to watch is $60.26. This is followed by the second major resistance level at $61.88. The third major resistance level sits at $64.47. If the price goes on to break the first support level at $56.05, it is likely to go to the next support level at $53.46. Should the price break the second support level, the third support level stands at $51.84.
Nektar Therapeutics (NASDAQ: NKTR) Key Stats
Market capitalization of the company is 1.19 billion based on 20,342K outstanding shares. Right now, sales total 98,430 K and income totals -118,960 K. The company made 11,790 K in profit during its latest quarter, and -35,520 K in sales during its previous quarter.
